Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00775450 · ClinicalTrials.gov registry record · Phase 2
Influenza Vaccine Revaccination in Ambulatory Elderly Subjects
A Phase 2 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 807
- Enrollment target
NCT00775450 is a Phase 2 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 807 participants.
The verdict
NCT00775450, a Phase 2 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 807 participants
- Enrollment target
Study Summary
This is a multi-center study designed to evaluate the safety and immunogenicity of a Fluzone revaccination in elderly adults aged ≥ 65 years. Primary Objective: To describe the safety profile for all subjects. Secondary Objective: To describe immunogenicity 28 days following revaccination with one of three Fluzone formulations.
Interventions
- BIOLOGICAL Influenza Virus Vaccine USP Trivalent Types A and B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 807 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00775450
The ClinicalTrials.gov registry entry for NCT00775450 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 807 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Influenza Virus Vaccine USP Trivalent Types A and B is the first listed.
NCT00775450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00775450 about?
NCT00775450 is a clinical study titled "Influenza Vaccine Revaccination in Ambulatory Elderly Subjects". This is a multi-center study designed to evaluate the safety and immunogenicity of a Fluzone revaccination in elderly adults aged ≥ 65 years. Primary Objective: To describe the safety profile for all subjects. Secondary Objective: To describe immunogenicity 28 days following revaccination with o...
What is the current status of trial NCT00775450?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 807 participants. The study started on 2008-10. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00775450?
The interventions under investigation include: Influenza Virus Vaccine USP Trivalent Types A and B (BIOLOGICAL).
Who is sponsoring clinical trial NCT00775450?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.